Jiangsu Institute of Parasitic Diseases, Wuxi, Jiangsu, People's Republic of China
Am J Trop Med Hyg. 2013 Jul;89(1):184-7. doi: 10.4269/ajtmh.12-0683. Epub 2013 May 13.
In central China, Plasmodium vivax accounts for all of the native reported cases of malaria. Chloroquine (CQ) plus primaquine (PQ) have been used for more than 60 years as the frontline drugs, but the risk of treatment failure remains unknown. To measure the effectiveness and safety of CQ-PQ among vivax malaria patients, a total of 39 subjects with monoinfection vivax malaria was enrolled in a study from 2008 to 2009. There were no recrudescence or danger signs observed within the 28-day follow-up period, showing that blood stage of P. vivax isolates from central China is still susceptible to CQ plus PQ combination therapy. However, the antirelapse efficacy of PQ is difficult to assess because of the high rate of loss to follow-up after 28 days; also, parasites persisted in a single case at 3 days post-antimalarial drug treatment, indicating that continuous annual monitoring is needed in central China.
在中国中部，所有报告的疟疾本地病例都是由间日疟原虫引起的。氯喹（CQ）加伯氨喹（PQ）已被用作一线药物 60 多年，但治疗失败的风险仍不清楚。为了衡量间日疟患者使用 CQ-PQ 的疗效和安全性，我们在 2008 年至 2009 年期间共招募了 39 例单纯间日疟原虫感染的患者进行研究。在 28 天的随访期间未观察到复发或危险迹象，表明来自中国中部的间日疟原虫分离株的血期仍然对 CQ 加 PQ 联合治疗敏感。然而，由于在 28 天后失访率较高，难以评估 PQ 的抗复发疗效；此外，在抗疟药物治疗后 3 天，有 1 例患者的寄生虫持续存在，这表明在中国中部需要进行连续的年度监测。
